14396 studies found for:    Canada
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
2 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
3 Enrolling by invitation Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
Condition: Ulcerative Colitis
4 Recruiting Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention
Condition: Acute Coronary Syndromes
Interventions: Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
5 Recruiting Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older
Conditions: Atrial Fibrillation;   Hypertension
Intervention: Device: Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)
6 Recruiting Observational Study of Golimumab Intravenous Infusion
Condition: Rheumatoid Arthritis
Intervention: Biological: Golimumab Intravenous
7 Recruiting A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Condition: Prostatic Neoplasms
Intervention: Other: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
8 Recruiting Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
9 Recruiting Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
Condition: Major Depressive Disorder
Intervention: Drug: vortioxetine
10 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
11 Recruiting Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol;   Drug: tiotropium
12 Recruiting Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MEDI4736;   Drug: Placebo
13 Recruiting A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Condition: Psoriasis
Interventions: Drug: Guselkumab 100 mg;   Drug: Placebo for guselkumab;   Drug: Adalimumab;   Drug: Placebo for adalimumab
14 Recruiting Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
Condition: Psoriasis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
15 Recruiting A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF);   Drug: vilanterol (VI);   Drug: umeclidinium bromide (UMEC)
16 Recruiting OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab
17 Recruiting A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
Condition: Asthma
Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid;   Drug: terbutaline 'as needed' + placebo budesonide bid;   Drug: budesonide bid + terbutaline 'as needed'
18 Recruiting A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Conditions: Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions: Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
19 Recruiting Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Condition: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
20 Active, not recruiting Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Condition: Hyperlipidemia
Interventions: Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years